Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine HBr as Adjunctive Treatment in Schizophrenia
NCT00077727Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Mar 2003
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
Phase 3, randomised, double-blind trial of galantamine in schizophrenia (3 arms), sponsored by Johnson & Johnson. Primary endpoints: Positive and Negative Syndrome Scale at 8 weeks, Brief Assessment of Cognition in Schizophrenia at 8 weeks and 2 more. Started Mar 2003; status: completed.
02
Drugs
galantamine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00077727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077727.